Aventure France 2030 ! 🏆 Hier, à Paris, se tenait le Comité interministériel de l’innovation C2i. Nous sommes fiers de faire partie de l’Aventure France 2030 ! pour rapprocher le futur et contribuer à l’excellence française dans la recherche...
Another step forward in the fight against sickle cell disease ! On the occasion of the state visit to France by Their Majesties King Frederik X and Queen Mary of Denmark, the 1st of April, Novo Nordisk signed a letter of intent to support the REVE (REVolutionizing...
Innovhem to present New data on single-cell quantification of HbF and HbS at the 2024 ASH Annual Meeting. One poster presentation to feature new data, highlighting the single-cell quantification of HbF and HbS on patients treated with hydroxyurea. Innovhem is a French...
Innovhem’s patents protect our BIOMARKERS : An important news ! SINGLE CELL QUANTIFICATION OF FETAL HEMOGLOBIN patent has been issued in France, Nigeria and in the US. And our 2 patents cover INTRAVASCULAR HEMOLYSIS ASSAY in Europe and in the US. Stay tuned for...
HEMOPROVE is an Open-label One Stage Phase II study sponsored by AP-HP. The investigator hypothesis is that the treatment by Voxelotor (GBT440) will improve intra vascular hemolysis and will increase the total mass of hemoglobin with beneficial effects on organ...
